Tet2-CHIP: From Mutation To Malady
Many people, especially as they age, can develop a condition called clonal hematopoiesis of indeterminate potential, or CHIP. This happens when a small group of blood stem cells, which are the “master” cells that make all other blood cells, acquire genetic changes and start to multiply more than other cells, but without immediately causing a blood cancer. While not a cancer itself, CHIP significantly increases the risk of developing blood cancers and, importantly, cardiovascular diseases like heart attacks and strokes. One of the most common genetic changes found in CHIP involves a gene called TET2. The TET2 gene normally plays a crucial role in controlling how our genes are turned on or off, a process known as epigenetic regulation. Specifically, it helps remove chemical tags from DNA, a process called DNA demethylation, which is essential for proper cell function and development. When TET2 is mutated, it loses its ability to perform this function, leading to an imbalance in gene regulation, often resulting in too many chemical tags on DNA (hypermethylation). This disruption causes blood stem cells to behave abnormally, leading to an overproduction of certain immune cells, particularly a type called macrophages. These altered macrophages, carrying the TET2 mutation, become more inflammatory and contribute to the buildup of plaque in arteries, a process known as atherosclerosis, which underlies many cardiovascular diseases. They can also upregulate certain receptors, like LDLR, further promoting plaque formation and instability. Understanding this link between TET2 mutations, CHIP, and cardiovascular disease is vital. While directly fixing a mutated TET2 gene is challenging, researchers are exploring new ways to counteract its effects. This includes looking for other genes or pathways that become essential when TET2 is faulty, known as “synthetic lethal” targets. For example, studies have shown that inhibiting certain enzymes like DOT1L or targeting the thrombopoietin receptor (TPO-R) signaling pathway can selectively reduce the growth advantage of cells with TET2 mutations, offering potential avenues for future treatments to prevent or mitigate the serious health consequences associated with this common genetic change.
Source: link to paper